FDA Peptide Compounding in 2026: What the July 23-24 PCAC Meeting Means

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

On July 23 and 24, 2026, the Food and Drug Administration's Pharmacy Compounding Advisory Committee will meet at the agency's White Oak campus in Silver Spring, Maryland, to review seven peptides nominated for the list of bulk drug substances that pharmacies are permitted to use when compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. [1] The meeting is the most consequential regulatory event for compounded peptides in several years. It will not, on its own, ban or approve anything. It will produce a formal recommendation that influences how the agency treats a class of substances that has grown quickly in the grey market, frequently without the batch testing that separates a characterized research compound from an unverified one.

This sits within the wider question of peptide legality. For how United States law treats peptides overall, see the overview on whether peptides are legal.

This article summarizes the published record: the meeting, the seven substances, the categories at issue, and the gap between an advisory vote and a final rule. It draws on the primary documents. Where a statement rests on reporting rather than an FDA filing, that is marked.

What the FDA announced

The notice of meeting was published in the Federal Register on April 16, 2026, at 91 FR 20465. [1] It established a public docket, FDA-2025-N-6895, and requested written comments and requests to make oral presentations. The committee will consider whether seven specific peptides should be placed on the 503A bulk drug substances list, the inventory of active ingredients that a 503A pharmacy may legally compound with when a substance is neither the subject of an applicable monograph nor a component of an FDA-approved drug.

The agenda spans two days, and the two days are not interchangeable. Each day covers a different set of substances, and each substance is reviewed in both its free-base and acetate forms. The committee advises; it does not decide. That distinction sits at the center of how the meeting should be read, and it is covered in detail below.

The seven peptides under review

The seven nominated substances are set out below, with the day each is scheduled and the use the FDA notice identifies as the basis for its safety evaluation. Two points of framing matter first. The use named for each substance restates what the agency's notice records as the reason for review. It is not a claim of efficacy, and none of these peptides is an FDA-approved drug for any use. The roster is the FDA's, assembled for a regulatory proceeding, and is reproduced here as published.

• BPC-157, reviewed July 23. Use the FDA notice identifies for evaluation: ulcerative colitis. Interim status: Category 2.
• KPV, reviewed July 23. Use the FDA notice identifies for evaluation: wound healing and inflammatory conditions. Interim status: Category 2.
• TB-500, reviewed July 23. Use the FDA notice identifies for evaluation: wound healing. Interim status: Category 2.
• MOTs-C, reviewed July 23. Use the FDA notice identifies for evaluation: obesity and osteoporosis. Interim status: Category 2.
• Emideltide, also referred to as delta sleep-inducing peptide or DSIP, reviewed July 24. Use the FDA notice identifies for evaluation: opioid withdrawal, chronic insomnia, and narcolepsy. Interim status: Category 2.
• Semax, reviewed July 24. Use the FDA notice identifies for evaluation: cerebral ischemia, migraine, and trigeminal neuralgia. Interim status: Category 2.
• Epitalon, reviewed July 24. Use the FDA notice identifies for evaluation: insomnia. Interim status: Category 2.

The descriptor "thymosin beta-4 fragment," sometimes attached to TB-500 in secondary write-ups, does not appear in the FDA notice and is not used here. The agency's filing names the substance as TB-500. The uses shown are the agency's evaluation parameters, recorded in the notice, and should be read as the questions the committee will weigh rather than as established findings. [1]

What the 503A bulk drug substances list is

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding: a pharmacist or physician compounding a drug for an individual patient pursuant to a prescription. A 503A pharmacy may compound using a bulk drug substance only if that substance meets one of three conditions. It is the subject of an applicable United States Pharmacopeia or National Formulary monograph, or it is a component of an FDA-approved drug, or it appears on a list the FDA develops of bulk substances that may be used in 503A compounding. [5] The seven peptides reach none of the first two conditions, which is why the third, the bulks list, is the entire question.

A related but separate pathway, section 503B, governs outsourcing facilities that compound at larger scale and operate under current good manufacturing practice. The 503B bulks list is its own inventory with its own evaluation. The July 2026 meeting concerns 503A. The two regimes are often conflated in consumer coverage, and they are not the same.

What "Category 2" means

While the FDA evaluates nominated substances, it sorts them into interim categories that signal its current enforcement posture. Category 1 covers substances that the agency has determined may be eligible for the bulks list and that do not appear to present a significant safety risk in compounding at this time; the FDA does not intend to take action against compounders who use them while review continues. [5] Category 2 is the cautionary tier. It covers substances for which the agency has identified significant safety risks pending further evaluation, and against which it would consider enforcement action if used in compounding. [6]

All seven peptides on the July agenda sit in Category 2 under the interim policy. That placement is the status quo the committee is convened to revisit. A nomination reaching the advisory committee is a step in the evaluation rather than a verdict, and Category 2 placement reflects the agency's caution rather than a final scientific conclusion.

What a PCAC vote does, and does not do

The Pharmacy Compounding Advisory Committee is an advisory body. Its function is to provide advice and recommendations to the FDA. [1] A committee vote does not function as a regulation, an approval, or a ban. It does not place any substance on, or remove any substance from, the bulks list. After the meeting, the agency weighs the committee's recommendation alongside the docket comments and its own analysis, and any change to the bulks list proceeds through notice-and-comment rulemaking, a process that unfolds over months rather than days.

Two consequences follow. A favorable committee recommendation does not make any peptide an approved drug or a settled-legal compounding ingredient; these substances remain unapproved drugs throughout. An unfavorable recommendation does not, by itself, criminalize anything that was lawful the day before. The meeting sets direction. The rule, if one follows, is what carries legal force.

How the public can participate

The docket, FDA-2025-N-6895, is open on Regulations.gov, and the Federal Register notice sets the dates that govern participation. [1] [4] Requests to make an oral presentation are due by June 30, 2026, and the agency notifies selected speakers by July 1. Written comments intended to reach the committee before it meets must be submitted on or before July 9, 2026; comments received after that date are entered into the record and considered by the FDA but may not reach committee members in advance. The electronic docket accepts comments through July 22, 2026. The meeting itself is hybrid, held in person at the White Oak Conference Center with an online teleconference option. Anyone tracking the proceeding can read the briefing materials the FDA posts shortly before the meeting on its 2026 committee-materials page. [7]

The wider regulatory context in 2026

The July meeting does not arrive in isolation. Through 2025 and into 2026, compounded peptides drew sustained attention from the agency and the compounding trade, and the interim Category 2 list saw active revision. Trade and legal coverage reported that the FDA republished the interim 503A bulks list in April 2026 and signaled changes to the categorization of a group of peptides. [8] The specific count, the exact roster of substances affected, and the precise mechanics of that republication are reported by law firms and trade outlets rather than stated in the meeting notice, and the figures vary between sources. Readers who need the operative list should consult the FDA's own bulk-substances inventory rather than the secondary summaries.

A second strand of coverage ties the heightened activity to the priorities of current Department of Health and Human Services leadership and the broader policy agenda around it. That connection appears in reporting from established outlets, including STAT and other life-sciences press. [9] It does not appear in the Federal Register notice, which contains no statement of political rationale. The causal framing is therefore presented here as reported context, attributed to those outlets, and not as the agency's stated reason for the review.

What happens next

After the committee votes, the FDA is expected to publish the meeting record and, in time, to act on the recommendation through its normal process. A decision to add a peptide to the 503A bulks list, or to leave it off, would be effected by rule, with the associated comment period and effective date. The timeline is not fixed by the meeting. Some coverage anticipates a further advisory meeting in early 2027 for additional substances, but no such meeting is scheduled in the primary record reviewed for this article, and the substances said to be deferred differ across sources. [8] The honest summary is that July 23 and 24 settle a recommendation rather than a rule, and the substantive legal change, in either direction, is the step that comes after.

For a brand that sources to ISO 17025 standards and tests every batch by HPLC and mass spectrometry, the meeting is worth following for a reason beyond the legal outcome. The proceeding turns on characterization and safety data, which is the same ground on which a tested research compound is distinguished from an untested grey-market one. The regulatory question and the quality question are closer than they appear.

Frequently asked questions

Is BPC-157 banned? No. As of the July 2026 meeting, BPC-157 sits in the FDA's interim Category 2 for 503A compounding, which signals caution and possible enforcement rather than a ban. It is an unapproved drug, and the committee meeting is a review step rather than a prohibition. [6]

Which peptides is the FDA reviewing in July 2026? Seven: BPC-157, KPV, TB-500, and MOTs-C on July 23, and Emideltide (DSIP), Semax, and Epitalon on July 24. Each is reviewed in free-base and acetate forms. [1]

What is the 503A bulks list? It is the FDA's list of bulk drug substances that 503A compounding pharmacies may use when the substance is not covered by a monograph and is not a component of an approved drug. A substance not on the list, and not otherwise qualifying, is not eligible for 503A compounding. [5]

Does a PCAC vote mean FDA approval? No. The committee is advisory. Its vote is a recommendation. Any change to the bulks list proceeds separately through rulemaking, and the peptides remain unapproved drugs regardless of the vote. [1]

When are the other peptides reviewed? The July meeting covers the seven substances listed above. Reporting has referred to a possible additional meeting in 2027, but the primary record reviewed here does not schedule one, and sources disagree on which substances it would cover. [8]

What is the difference between 503A and 503B? Section 503A covers traditional, prescription-specific compounding by pharmacies. Section 503B covers larger-scale outsourcing facilities operating under current good manufacturing practice. Each has its own bulk-substances list. The July 2026 meeting concerns 503A. [5]

Sources

1. Food and Drug Administration. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments." Federal Register, 91 FR 20465, April 16, 2026. Docket FDA-2025-N-6895. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
2. Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Advisory Committee Calendar. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
3. Regulations.gov. "Docket FDA-2025-N-6895." https://www.regulations.gov/docket/FDA-2025-N-6895
4. Food and Drug Administration. "Public-inspection notice (FR Doc. 2026-07361)." https://public-inspection.federalregister.gov/2026-07361.pdf
5. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
6. Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks." https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
7. Food and Drug Administration. "2026 Meeting Materials, Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/2026-meeting-materials-pharmacy-compounding-advisory-committee
8. Reported in compounding-industry and legal trade coverage (for example, Regulatory Affairs Professionals Society and law-firm regulatory alerts), April 2026. Secondary sources; consult the FDA bulk-substances inventory for the operative list.
9. Reported in life-sciences press coverage of FDA compounding policy and HHS priorities, 2026. Secondary sources, presented as context rather than as the agency's stated rationale.